Compare CAL & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAL | VIR |
|---|---|---|
| Founded | 1878 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.3M | 1.5B |
| IPO Year | 1994 | 2019 |
| Metric | CAL | VIR |
|---|---|---|
| Price | $10.51 | $8.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $15.00 | ★ $19.63 |
| AVG Volume (30 Days) | 682.0K | ★ 2.8M |
| Earning Date | 03-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $85,513,000.00 | $68,556,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $3.25 | $1,049.62 |
| P/E Ratio | $22.06 | ★ N/A |
| Revenue Growth | ★ 0.46 | N/A |
| 52 Week Low | $8.80 | $4.16 |
| 52 Week High | $18.08 | $10.91 |
| Indicator | CAL | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 50.96 |
| Support Level | $10.33 | $8.67 |
| Resistance Level | $13.55 | $10.29 |
| Average True Range (ATR) | 0.59 | 0.46 |
| MACD | 0.13 | -0.15 |
| Stochastic Oscillator | 54.81 | 40.57 |
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.